Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Proc Natl Acad Sci U S A ; 117(47): 29959-29967, 2020 11 24.
Artigo em Inglês | MEDLINE | ID: mdl-33177239

RESUMO

Glucagon-like peptide-1 receptor (GLP-1R) agonists are efficacious antidiabetic medications that work by enhancing glucose-dependent insulin secretion and improving energy balance. Currently approved GLP-1R agonists are peptide based, and it has proven difficult to obtain small-molecule activators possessing optimal pharmaceutical properties. We report the discovery and mechanism of action of LY3502970 (OWL833), a nonpeptide GLP-1R agonist. LY3502970 is a partial agonist, biased toward G protein activation over ß-arrestin recruitment at the GLP-1R. The molecule is highly potent and selective against other class B G protein-coupled receptors (GPCRs) with a pharmacokinetic profile favorable for oral administration. A high-resolution structure of LY3502970 in complex with active-state GLP-1R revealed a unique binding pocket in the upper helical bundle where the compound is bound by the extracellular domain (ECD), extracellular loop 2, and transmembrane helices 1, 2, 3, and 7. This mechanism creates a distinct receptor conformation that may explain the partial agonism and biased signaling of the compound. Further, interaction between LY3502970 and the primate-specific Trp33 of the ECD informs species selective activity for the molecule. In efficacy studies, oral administration of LY3502970 resulted in glucose lowering in humanized GLP-1R transgenic mice and insulinotropic and hypophagic effects in nonhuman primates, demonstrating an effect size in both models comparable to injectable exenatide. Together, this work determined the molecular basis for the activity of an oral agent being developed for the treatment of type 2 diabetes mellitus, offering insights into the activation of class B GPCRs by nonpeptide ligands.


Assuntos
Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas , Hipoglicemiantes/farmacologia , Domínios Proteicos/genética , Administração Oral , Aminopiridinas/farmacologia , Animais , Fármacos Antiobesidade/farmacologia , Benzamidas/farmacologia , Microscopia Crioeletrônica , Receptor do Peptídeo Semelhante ao Glucagon 1/genética , Receptor do Peptídeo Semelhante ao Glucagon 1/metabolismo , Receptor do Peptídeo Semelhante ao Glucagon 1/ultraestrutura , Células HEK293 , Humanos , Incretinas/farmacologia , Macaca fascicularis , Masculino , Camundongos , Camundongos Transgênicos , Modelos Moleculares , Mutagênese Sítio-Dirigida , Ratos , Especificidade da Espécie , Suínos , Triptofano/genética
2.
Kidney Int ; 98(2): 343-354, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32624180

RESUMO

Chronic kidney disease is characterized as impaired renal function along with the imbalance and dysregulation of mineral metabolism; recognized as chronic kidney disease-mineral and bone disorder. Hyperphosphatemia, characterized by altered phosphate homeostasis along with elevated fibroblast growth factor-23 and intact parathyroid hormone, is such an alteration of mineral metabolism. We discovered a novel inhibitor, EOS789, that interacts with several sodium-dependent phosphate transporters (NaPi-IIb, PiT-1, and PiT-2) known to contribute to intestinal phosphate absorption. This inhibitor dose-dependently increased the fecal phosphorus excretion rate and inversely decreased the urinary phosphorus excretion rate in normal rats, suggesting inhibition of intestinal phosphorus absorption. In rats with adenine-induced hyperphosphatemia, EOS789 markedly decreased the serum phosphate, fibroblast growth factor-23, and intact parathyroid hormone below values found in normal control rats. Notably, this pan-phosphate transporter inhibitor exhibited a more potent effect on serum phosphate than a NaPi-IIb-selective inhibitor in rats with hyperphosphatemia indicating that PiT-1 and PiT-2 play important roles in intestinal phosphate absorption. Moreover, in a long-term study, EOS789 sustained the suppression of serum phosphorus in parallel with fibroblast growth factor-23 and intact parathyroid hormone and ameliorated ectopic calcification of the thoracic aorta. Additionally, EOS789 treatment also ameliorated kidney deterioration in rats with progressive kidney injury, probably due to the strict phosphate control. Thus, EOS789 has potent efficacy against hyperphosphatemia and its complications and could provide a significant benefit to patients who are ineffectively treated with phosphate binders.


Assuntos
Distúrbio Mineral e Ósseo na Doença Renal Crônica , Hiperfosfatemia , Insuficiência Renal Crônica , Animais , Humanos , Hiperfosfatemia/tratamento farmacológico , Minerais , Proteínas de Transporte de Fosfato , Fosfatos/metabolismo , Ratos , Insuficiência Renal Crônica/tratamento farmacológico
3.
Xenobiotica ; 47(12): 1042-1051, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27841077

RESUMO

1. A novel selective anaplastic lymphoma kinase (ALK) inhibitor, alectinib, has shown remarkable efficacy and safety in patients with ALK-positive non-small-cell lung cancer (NSCLC). The purpose of this study was to evaluate in vitro the potential to inhibit and induce cytochrome P450 (CYP) isoforms for alectinib and its major metabolite M4. 2. Alectinib and M4 did not show the meaningful direct inhibition of six major CYP isoforms (CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4) in human liver microsomes (HLM). Alectinib, but not M4, competitively inhibited CYP2C8, by which few marketed drugs are exclusively metabolized, with an inhibition constant of 1.98 µM. 3. Out of the seven CYP isoforms in HLM, alectinib and M4 showed time-dependent inhibition (TDI) of only CYP3A4, which suggests low TDI potential due to low inactivation efficiency. 4. Alectinib exhibited quite smaller induction of mRNA expression of CYP1A2, 2B6 and 3A4 genes in human hepatocytes compared to the respective positive controls, suggesting a low potential of enzyme induction. 5. In summary, the risk of alectinib causing drug-drug interactions with coadministered drugs is expected to be low due to the weak potential of CYP inhibition and induction estimated in the preclinical studies.


Assuntos
Carbazóis/farmacologia , Inibidores das Enzimas do Citocromo P-450/farmacologia , Sistema Enzimático do Citocromo P-450/metabolismo , Piperidinas/farmacologia , Quinase do Linfoma Anaplásico , Indução Enzimática/efeitos dos fármacos , Receptores Proteína Tirosina Quinases/metabolismo
4.
Xenobiotica ; 45(3): 230-8, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25350082

RESUMO

Abstract 1. The metabolism and drug-drug interaction (DDI) risk of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, were evaluated by in vitro studies using human liver microsomes, human hepatocytes, and recombinant human CYPs. 2. The main metabolite of tofogliflozin was the carboxylated derivative (M1) in human hepatocytes, which was the same as in vivo. The metabolic pathway of tofogliflozin to M1 was considered to be as follows: first, tofogliflozin was catalyzed to the primary hydroxylated derivative (M4) by CYP2C18, CYP4A11 and CYP4F3B, then M4 was oxidized to M1. 3. Tofogliflozin had no induction potential on CYP1A2 and CYP3A4. Neither tofogliflozin nor M1 had inhibition potential on CYPs, with the exception of a weak CYP2C19 inhibition by M1. 4. Not only are multiple metabolic enzymes involved in the tofogliflozin metabolism, but the drug is also excreted into urine after oral administration, indicating that tofogliflozin is eliminated through multiple pathways. Thus, the exposure of tofogliflozin would not be significantly altered by DDI caused by any co-administered drugs. Also, tofogliflozin seems not to cause significant DDI of co-administered drugs because tofogliflozin has no CYP induction or inhibition potency, and the main metabolite M1 has no clinically relevant CYP inhibition potency.


Assuntos
Compostos Benzidrílicos/metabolismo , Glucosídeos/metabolismo , Hepatócitos/metabolismo , Metabolômica/métodos , Microssomos Hepáticos/metabolismo , Inibidores do Transportador 2 de Sódio-Glicose , Compostos Benzidrílicos/química , Radioisótopos de Carbono , Coenzimas/metabolismo , Inibidores das Enzimas do Citocromo P-450/farmacologia , Sistema Enzimático do Citocromo P-450/biossíntese , Interações Medicamentosas , Indução Enzimática/efeitos dos fármacos , Glucosídeos/química , Hepatócitos/efeitos dos fármacos , Hepatócitos/enzimologia , Humanos , Concentração Inibidora 50 , Redes e Vias Metabólicas/efeitos dos fármacos , Metaboloma/efeitos dos fármacos , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/enzimologia , Ligação Proteica/efeitos dos fármacos , Proteínas Recombinantes/metabolismo , Transportador 2 de Glucose-Sódio/metabolismo , Fatores de Tempo
5.
Drug Metab Dispos ; 42(9): 1540-7, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25005602

RESUMO

The accurate prediction for the body clearance of a novel drug candidate by humans during the preclinical stage contributes to its successful development. To improve the predictability of human hepatic clearance, we focused on CYP3A4, which is involved in the metabolism of more than 50% of all currently marketed drugs. In this study, we investigated the validity of the in vivo model using transgenic mice carrying the human CYP3A4 gene and lacking their own Cyp3a genes (CYP3A4-Tg mice). The CYP3A4 activity toward its substrates in liver microsomes was similar in CYP3A4-Tg mice and humans. As for the clearance, six CYP3A4 substrates (alprazolam, felodipine, midazolam, nifedipine, nitrendipine, and quinidine) were given intravenously to CYP3A4-Tg mice, and their hepatic intrinsic clearance (CLint,h) was evaluated. A regression analysis of the data obtained indicated that the CLint,h values of six substrates in CYP3A4-Tg mice were highly correlated with those in humans (R(2) = 0.95). This correlation could be improved by correcting the CLint,h values by the relative contribution of artificially expressed CYP3A4 to the overall metabolism in the mice. From these findings, it is reasonable to expect that the CLint,h of a particular drug in humans is predictable by applying the CLint,h obtained in CYP3A4-Tg mice to a regression line prepared in advance. The variance of the CLint,h prediction by this method was evaluated and found to be within a range of 2-fold of the regression value. These results suggest that the CYP3A4-Tg mouse model has the potential to accurately predict the human hepatic clearance of CYP3A4 substrates.


Assuntos
Citocromo P-450 CYP3A/metabolismo , Sistema Enzimático do Citocromo P-450/metabolismo , Microssomos Hepáticos/metabolismo , Alprazolam/metabolismo , Animais , Felodipino/metabolismo , Humanos , Masculino , Camundongos , Camundongos Transgênicos , Midazolam/metabolismo , Nifedipino/metabolismo , Nitrendipino/metabolismo , Quinidina/metabolismo
6.
Cancer Chemother Pharmacol ; 65(2): 363-71, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19495753

RESUMO

PURPOSE: Identification of a novel topoisomerase I inhibitor which shows superior efficacy and less individual variation than irinotecan hydrochloride (CPT-11). METHODS: A novel camptothecin analog that is effective against breast cancer resistance protein (BCRP)-positive cells was screened, and a water soluble prodrug was generated. Antitumor activity of the prodrug was examined in BCRP-positive and -negative xenografts both as a single agent and in combination with other anti-cancer drugs. RESULTS: A novel camptothecin analog, CH0793076, was discovered. Because CH0793076 was found to be highly lipophilic, a water soluble prodrug (TP300) was generated. TP300 is stable in an acidic solution but is rapidly converted to CH0793076 under physiological pH conditions such as in sera. This efficient prodrug activation would minimize interpatient differences in pharmacokinetic and toxicity profiles. Unlike CPT-11, TP300 does not exhibit cholinergic interaction or cause acute diarrhea at effective doses. In mouse xenograft models, TP300 showed antitumor activity against both BCRP-positive and -negative xenografts, whereas CPT-11 was less active against BCRP-positive xenografts. In addition, the effective dose range (MTD/ED(50)) for TP300 was wider than for CPT-11 and TP300 showed additive or synergistic antitumor effects in combination with other anti-cancer drugs such as capecitabine, oxaliplatin, cisplatin, bevacizumab and cetuximab. CONCLUSION: It is therefore expected that TP300 will provide an additional treatment option for patients who will undergo chemotherapy with camptothecins.


Assuntos
Transportadores de Cassetes de Ligação de ATP/biossíntese , Antineoplásicos/uso terapêutico , Camptotecina/análogos & derivados , Dipeptídeos/uso terapêutico , Compostos Heterocíclicos de 4 ou mais Anéis/uso terapêutico , Proteínas de Neoplasias/biossíntese , Pró-Fármacos/uso terapêutico , Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP , Acetilcolinesterase/metabolismo , Animais , Antineoplásicos/farmacologia , Camptotecina/farmacologia , Camptotecina/uso terapêutico , Linhagem Celular Tumoral , Dipeptídeos/farmacologia , Resistencia a Medicamentos Antineoplásicos , Sinergismo Farmacológico , Compostos Heterocíclicos de 4 ou mais Anéis/farmacologia , Humanos , Irinotecano , Masculino , Camundongos , Camundongos Nus , Pró-Fármacos/farmacologia , Solubilidade , Água , Ensaios Antitumorais Modelo de Xenoenxerto
7.
Bioorg Med Chem Lett ; 19(10): 2772-6, 2009 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-19362835

RESUMO

CH0793076 (1) is a novel hexacyclic camptothecin analog showing potent antitumor activity in various human caner xenograft models. To improve the water solubility of 1, water-soluble prodrugs were designed to generate an active drug 1 nonenzymatically, thus expected to show less interpatient PK variability than CPT-11. Among the prodrugs synthesized, 4c (TP300, hydrochloride) having a glycylsarcosyl ester at the C-20 position of 1 is highly water-soluble (>10mg/ml), stable below pH 4 and rapidly generates 1 at physiological pH in vitro. The rapid (ca. <1min) generation of 1 after incubation of TP300 with plasma (mouse, rat, dog and monkey) was also demonstrated. TP300 showed a broader antitumor spectrum and more potent antitumor activity than CPT-11 in various human cancer xenograft models.


Assuntos
Antineoplásicos/síntese química , Camptotecina/análogos & derivados , Pró-Fármacos/síntese química , Animais , Antineoplásicos/sangue , Antineoplásicos/farmacocinética , Camptotecina/sangue , Camptotecina/síntese química , Camptotecina/química , Camptotecina/farmacocinética , DNA Topoisomerases Tipo I/metabolismo , Cães , Haplorrinos , Humanos , Concentração de Íons de Hidrogênio , Irinotecano , Camundongos , Camundongos Nus , Pró-Fármacos/química , Pró-Fármacos/farmacocinética , Ratos , Inibidores da Topoisomerase I , Transplante Heterólogo , Água/química
8.
Drug Metab Pharmacokinet ; 20(4): 244-56, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16141604

RESUMO

We examined the design of the versatile novel self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion formulation which enhances the oral bioavailability by raising the solubility of poorly water soluble compounds. Namely, seven kinds of poorly water soluble compounds such as disopyramide, ibuprofen, ketoprofen, tolbutamide, and other new compounds, as the model compounds were used to compare the plasma concentration profile of the compound following single oral administration of each compound to rats and beagle dogs as a solution, an oily solution, a suspension (or a powder), an O/W microemulsion, and a SEDDS type O/W microemulsion. And the enhancing effect of the SEDDS type O/W microemulsion on the gastrointestinal absorption of these compounds was evaluated. In the components of the SEDDS type O/W microemulsion, medium chain fatty acid triglyceride (MCT), diglyceryl monooleate (DGMO-C), polyoxyethylene hydrogenated castor oil 40 (HCO-40), and ethanol were used as an oil, a lipophilic surfactant, a hydrophilic surfactant, and a solubilizer, at the mixture ratio of 25/5/45/25 (w/w%), respectively. Thereby, to six kinds of the model compounds except disopyramide, the solubility was from 340 to 98,000 times that in water, and the AUCs in plasma concentration of the compound were equivalent to that of solution or O/W microemulsion administration, or was increased by 1.5 to 78 times that of suspension administration. Accordingly, this novel SEDDS type O/W microemulsion is the versatile, useful formulation which enhances the oral bioavailability by raising the solubility of poorly water soluble compounds.


Assuntos
Benzofuranos/administração & dosagem , Sistemas de Liberação de Medicamentos , Emulsões/administração & dosagem , Indóis/administração & dosagem , Animais , Área Sob a Curva , Benzofuranos/sangue , Benzofuranos/farmacocinética , Disponibilidade Biológica , Cães , Desenho de Fármacos , Emulsões/química , Mucosa Gástrica/metabolismo , Ibuprofeno/administração & dosagem , Ibuprofeno/sangue , Ibuprofeno/farmacocinética , Indóis/sangue , Indóis/farmacocinética , Cetoprofeno/administração & dosagem , Cetoprofeno/sangue , Cetoprofeno/farmacocinética , Lipídeos/química , Masculino , Tamanho da Partícula , Ratos , Ratos Sprague-Dawley , Solubilidade , Tensoativos/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...